A PHASE IIb RANDOMISED DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-00610355 OVER 4 WEEKS IN MODERATE ASTHMATIC SUBJECTS

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To assess the efficacy of PF-00610355 (‘once daily’ QD doses of 100 mcg, 300 mcg and 600 mcg) in the treatment of moderate asthma following 4 weeks treatment.

Critère d'inclusion

Asthma

Liens

ictrp
euctr